JEFF EVANS

4.8k total citations · 1 hit paper
24 papers, 1.2k citations indexed

About

JEFF EVANS is a scholar working on Oncology, Immunology and Cancer Research. According to data from OpenAlex, JEFF EVANS has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Immunology and 6 papers in Cancer Research. Recurrent topics in JEFF EVANS's work include Immunotherapy and Immune Responses (5 papers), CAR-T cell therapy research (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). JEFF EVANS is often cited by papers focused on Immunotherapy and Immune Responses (5 papers), CAR-T cell therapy research (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). JEFF EVANS collaborates with scholars based in United Kingdom, United States and Australia. JEFF EVANS's co-authors include Gordon W. McLean, Margaret C. Frame, Valerie G. Brunton, Egle Avizienyte, Neil O. Carragher, Patricia S. Steeg, James W.A. Ritchie, Sally Kinrade, Mark Sullivan and Jacqui Shaw and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature reviews. Cancer.

In The Last Decade

JEFF EVANS

21 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The role of focal-adhesion kinase in cancer — a new therapeutic opportunity

2005 855 citations Gordon W. McLean, Neil O. Carragher et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
JEFF EVANS United Kingdom	6	617	414	397	278	272	24	1.2k
Datsun A. Hsia United States	12	841 1.4×	796 1.9×	383 1.0×	324 1.2×	559 2.1×	13	1.6k
Julio A. Aguirre Ghiso Argentina	12	606 1.0×	371 0.9×	543 1.4×	686 2.5×	213 0.8×	16	1.3k
Andreas Menrad Germany	20	682 1.1×	162 0.4×	513 1.3×	206 0.7×	141 0.5×	30	1.5k
Gaynor Davies United Kingdom	19	576 0.9×	141 0.3×	351 0.9×	255 0.9×	107 0.4×	22	1.0k
Sujatha Jagadeeswaran United States	12	465 0.8×	121 0.3×	360 0.9×	197 0.7×	87 0.3×	16	973
Jae Youn Yi South Korea	20	847 1.4×	129 0.3×	453 1.1×	172 0.6×	214 0.8×	37	1.3k
Ryoji Hamanaka Japan	18	1.2k 2.0×	120 0.3×	613 1.5×	345 1.2×	792 2.9×	34	1.8k
Kozłowski Jm United States	3	844 1.4×	417 1.0×	565 1.4×	504 1.8×	266 1.0×	9	1.7k
Isa M. Hussaini United States	19	935 1.5×	187 0.5×	401 1.0×	434 1.6×	196 0.7×	28	1.5k
Simonetta Buglioni Italy	22	930 1.5×	176 0.4×	772 1.9×	511 1.8×	130 0.5×	71	1.7k

Countries citing papers authored by JEFF EVANS

Since Specialization

Citations

This map shows the geographic impact of JEFF EVANS's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JEFF EVANS with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JEFF EVANS more than expected).

Fields of papers citing papers by JEFF EVANS

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JEFF EVANS. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JEFF EVANS. The network helps show where JEFF EVANS may publish in the future.

Co-authorship network of co-authors of JEFF EVANS

This figure shows the co-authorship network connecting the top 25 collaborators of JEFF EVANS. A scholar is included among the top collaborators of JEFF EVANS based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JEFF EVANS. JEFF EVANS is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barclay, Stephen, Matthew Priest, Ewan Forrest, et al.. (2024). Comparison between patient characteristics, aetiology and outcomes in patients with and without cirrhosis with hepatocellular carcinoma diagnosed in a regional centre. Frontline Gastroenterology. 15(5). 380–386. 1 indexed citations

Basu, Bristi, Adrian Mander, Richard J. A. Goodwin, et al.. (2021). Abstract CT214: ATRiUM: A first-in-human dose escalation phase I trial of ceralasertib (AZD6738) and gemcitabine as combination therapy. Cancer Research. 81(13_Supplement). CT214–CT214. 1 indexed citations

Drake, Thomas M, Ewan Forrest, Stephen T. Barclay, et al.. (2021). Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study. Journal of Clinical Medicine. 10(13). 2770–2770. 11 indexed citations

Tzankov, Alexandar, Ruth Plummer, Igor Vivanco, et al.. (2020). 382P The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM). Annals of Oncology. 31. S404–S404. 2 indexed citations

Stradella, Agostina, Melissa L. Johnson, Sanjay Goel, et al.. (2020). 530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ). Annals of Oncology. 31. S465–S466. 1 indexed citations

Wilson, Christina, Janet Graham, JEFF EVANS, et al.. (2019). The downstaging approach to irresectable oesophageal and gastric cancer: a single centre experience. Journal of Gastrointestinal Oncology. 10(3). 499–505. 1 indexed citations

Sarker, Debashis, Ruth Plummer, Bristi Basu, et al.. (2019). First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-α, in patients with advanced hepatocellular cancer (HCC). Annals of Oncology. 30. v168–v169. 4 indexed citations

Cook, Natalie, Udai Banerji, JEFF EVANS, et al.. (2019). Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours. Annals of Oncology. 30. v174–v174. 16 indexed citations

Anderson, Robin L., Juliana Callaghan, R. Charles Coombes, et al.. (2018). A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology. 16(3). 185–204. 245 indexed citations

10.

Neves, Karla B, Francisco J. Rios, Robert J. Jones, et al.. (2018). A10228 Endothelial microparticles from vegf inhibitor (vegfi)-treated cancer patients mediates endothelial cell signaling and et-1 production. Journal of Hypertension. 36. e58–e59.

11.

Edeline, Julien, Jean‐Frédéric Blanc, Philip J. Johnson, et al.. (2016). A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver International. 36(12). 1821–1828. 75 indexed citations

12.

Middleton, Mark R., Pippa Corrie, Mario Sznol, et al.. (2015). Abstract CT106: A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma. Cancer Research. 75(15_Supplement). CT106–CT106. 5 indexed citations

13.

Asmal, Mohammed, Emma Dean, JEFF EVANS, Mark R. Middleton, & Ruth Plummer. (2015). VX-970, selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein. Annals of Oncology. 26. ii8–ii8. 1 indexed citations

14.

Middleton, Mark R., JEFF EVANS, Neil Steven, et al.. (2014). A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma. Cancer Research. 74. 1 indexed citations

15.

EVANS, JEFF, Malcolm J. Moore, Eric Van Cutsem, et al.. (2014). Phase 2 Double-Blind, Placebo–Controlled Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer (LAPC). Annals of Oncology. 25. ii105–ii105. 2 indexed citations

16.

Middleton, Mark R., JEFF EVANS, Neil Steven, et al.. (2014). Abstract CT329: A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma. Cancer Research. 74(19_Supplement). CT329–CT329. 1 indexed citations

17.

Shapiro, Geoffrey I., Rebecca Kristeleit, Mark R. Middleton, et al.. (2013). Abstract A218: Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 12(11_Supplement). A218–A218. 8 indexed citations

18.

Barton, John H., Dianna Shipley, Edward Arrowsmith, et al.. (2009). Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer. Journal of Clinical Oncology. 27(15_suppl). 1091–1091. 5 indexed citations

19.

Arkenau, Hendrik‐Tobias, JEFF EVANS, Patricia Roxburgh, et al.. (2009). A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer. Journal of Clinical Oncology. 27(15_suppl). 3584–3584. 2 indexed citations

20.

McLean, Gordon W., Neil O. Carragher, Egle Avizienyte, et al.. (2005). The role of focal-adhesion kinase in cancer — a new therapeutic opportunity. Nature reviews. Cancer. 5(7). 505–515. 855 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact